Table 1.
Main Characteristics of Hospitalized Patients Treated With Molnupiravir.
| Main Characteristics of Hospitalized Patients Treated with Molnupiravir n = 44 (100%) | |
|---|---|
| Age (median, years) | 79 (IQR range, 51–93)
|
| Sex | Male 27 (57.4) |
| Past Smoker | 4 (8.5) |
| BMI | 21.5 (IQR range, 18.7–30.1) |
| Scores | |
| CCI | 5 (IQR range, 3–10) |
| 4C | 9.9 (IQR range, 4–12) |
| Comorbidities | |
| Cardiovascular diseases | 32 (68.1) |
| CKD | 14 (29.8) |
| Pulmonary diseases | 12 (25.5) |
| Neurologic diseases | 10 (21.3) |
| Solid tumor | 9 (19.1) |
| Haematological diseases | 5 (10.6) |
| Diabetes | 15 (31.9) |
| SOT | 1 (2.1) |
| Rheumatologic diseases | 2 (4.5) |
| Reason of Admission in Hospital | |
| Heart failure | 9 (20.4) |
| Liver failure | 4 (8.5) |
| Anemia | 3 (6.8) |
| Femoral neck fracture | 3 (6.4) |
| CAP | 2 (4.3) |
| Gastrointestinal Diseases | 3 (6.4) |
| Neurological Diseases | 2 (4.5) |
| Cancer | 2 (4.5) |
| UTI | 3 (6.4) |
| Previous COVID-19 or SARS-CoV-2 Vaccination | |
| Previous COVID-19 | 3 (6.4%) |
| V0 | 5 (10.6) |
| V1 | 0 |
| V2 | 8 (17) |
| V3 | 31 (66) |
| First doses | 39 (30 BioNTech/Pfizer; 8 Moderna; 1 Johnson and Johnson) |
| Second doses | 39 (31 BioNTech/Pfizer; 8 Moderna) |
| Third Doses | 31 (24 BioNTech/Pfizer; 7 Moderna) |
| Previous Oxygen for Chronic O2-therapynd Start Oxygen after SARS-CoV- | |
| Patients in O2-therapy before molnupiravir | 8 (18.1) |
| Start O2 during molnupiravir or increase | 8 (18.1) |
| Hospital acquired infections | |
| Nosocomial superinfections | 5 (10.5) |
| UTI | 4 (Escherichia coli ESBL, Proteus mirabilis, Enterococcus faecium Vancomycin-resistant; Klebsiella oxytoca) |
| BSI | 1 (Enterococcus faecium Vancomycin-resistant) |
| Events during molnupiravir Treatment | |
| Adverse events during Molnupiravir | 0 (0) |
| Pill missed | 0 (0) |
| Outcomes | |
| Survival | 39 (88.6) |
| Time to positivity and SARS-CoV-2 positivity | |
| Time from last vaccination to SARS-CoV-2 positivity | 96.8 (7–240) days |
| Time from admission to SARS-CoV-2 S/S start | 15 (5–33) days |
Abbreviations: IQR: interquartile range; CCI: Charlson comorbidity index; 4C: four “C” score; CKD: chronic kidney disease; SOT: solid organ transplant; CAP: community acquired pneumonia; UTI: urinary tract infection; V: vaccine; O2: oxygen; BMI: body mass index; UTI: urinary tract infection; BSI: blood-stream infection; ESBL: extended-spectrum Beta-lactamases; S/S: signs or symptoms.